Connecticut biotech Veradermics gets $150M for Phase 3 trials of oral Rogaine

Veradermics has raised the week's second megaround for a hair loss biotech, collecting a $150 million Series C from prominent life sciences investors. The New Haven, CT-based biotech plans to use the funding to get ...